Abbott Laboratories 10-Q Summary
Business Context and Reporting Period
Abbott Laboratories filed an unaudited Form 10-Q for the quarter and six months ended June 30, 2021. The company operates through Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. Results were significantly affected by demand for COVID-19 diagnostic tests and recovery in medical-procedure volumes from 2020 pandemic-related disruptions.
Financial Performance and Key Metrics
| Metric | Three Months Ended June 30, 2021 | Year-over-Year Change | Six Months Ended June 30, 2021 | Year-over-Year Change |
|---|---|---|---|---|
| Net sales | $10.223 billion | 39.5% | $20.679 billion | 37.4% |
| Operating earnings | $1.392 billion | 107.1% | $3.501 billion | 144.8% |
| Earnings from continuing operations | $1.189 billion | 121.2% | $2.982 billion | 175.8% |
| Net earnings | $1.189 billion | 121.2% | $2.982 billion | 170.8% |
| Diluted EPS | $0.66 | 120.0% | $1.66 | 172.1% |
- Margins: Gross margin was 46.7% in the second quarter versus 47.9% in the prior-year quarter, primarily due to a $499 million COVID-19 diagnostic manufacturing restructuring charge. Six-month gross margin was 49.9% versus 49.1%. Operating margin was approximately 13.6% for the quarter and 16.9% for the six months; net margin was approximately 11.6% and 14.4%, respectively.
- Segment sales: Second-quarter sales increased 16.4% in Established Pharmaceuticals, 11.9% in Nutritionals, 62.8% in Diagnostics, and 51.3% in Medical Devices. Six-month sales increased 9.4%, 9.4%, 90.0%, and 30.3%, respectively.
- COVID-19 testing: Testing-related sales were approximately $1.3 billion in the second quarter and $3.5 billion in the first six months, compared with approximately $0.6 billion in the comparable 2020 periods. Rapid Diagnostics sales increased 245.7% in the first six months.
- Cash flow: Six-month operating cash flow was $4.765 billion versus $2.037 billion in 2020. Investing activities used $686 million, primarily including $810 million of capital expenditures. Financing activities used $2.231 billion, including $1.603 billion of dividends and $746 million of share repurchases.
- Liquidity: Cash and cash equivalents were $8.658 billion at June 30, 2021, compared with $6.838 billion at December 31, 2020. Working capital increased to $10.0 billion from $8.5 billion.
- Debt: Current and long-term debt totaled approximately $18.5 billion at June 30, 2021, compared with $18.7 billion at year-end 2020. Abbott reported $5.0 billion of available credit lines expiring in 2025, an A+ long-term rating from S&P, and an A2 rating from Moody’s.
- Shareholder returns: The quarterly dividend was $0.45 per share, up 25% from $0.36. Abbott repurchased 4.5 million shares for $502 million in June; $2.595 billion remained available under the 2019 repurchase authorization.
Material Changes Versus the Prior Comparable Period
- Sales growth was led by COVID-19 diagnostic testing, particularly BinaxNOW, Panbio, and ID NOW, as well as increased medical-device procedure volumes and continued FreeStyle Libre growth.
- FreeStyle Libre and Libre Sense sales reached $1.733 billion for the first six months, up 36.3% excluding foreign exchange.
- Operating earnings benefited from higher sales volumes, favorable utilization, lower amortization, and the nonrecurrence of 2020 equity-investment impairments. These benefits were partly offset by higher research and development, selling and marketing, litigation, and restructuring costs.
- Foreign exchange increased international sales by 7.0% in the quarter and 5.4% for the six months; reported sales growth excluding foreign exchange was 35.0% and 33.9%, respectively.
- Cash generation improved substantially, partly because pension contributions declined to $80 million from $335 million and despite cash taxes increasing to approximately $715 million from $285 million.
Guidance, Outlook, Risks, and Unusual Items
- Restructuring: Abbott expects total pre-tax costs of approximately $500 million to $625 million to realign its COVID-19 diagnostic manufacturing network. It recorded $499 million in the second quarter, including $248 million of inventory charges, $80 million of fixed-asset write-downs, and $171 million of other exit costs. The actions are expected to be substantially complete by year-end 2021, with approximately $152 million of related accrued costs remaining at June 30.
- Outlook: The filing does not provide a clear quantitative earnings or revenue guidance range. Management cautions that the duration and impact of the COVID-19 pandemic remain uncertain, including the effect of vaccination rates, testing guidance, infection levels, and future demand for COVID-19 tests.
- Litigation and contingencies: The estimated range of possible legal and environmental losses was approximately $255 million to $280 million, with an accrual of approximately $265 million. Management stated that the ultimate disposition is not expected to materially adversely affect financial position, cash flows, or results of operations.
- Taxes: Abbott believes approximately $80 million of gross unrecognized tax benefits, including cash adjustments, may decrease within the next 12 months as tax matters are resolved.
- Other unusual items: Other income included a gain on the sale of an equity-method investment and the absence of approximately $60 million of second-quarter 2020 equity-investment impairments. Annual intangible-asset amortization was estimated at approximately $2.0 billion in 2021 and 2022.
- Principal risks: Key risks include changes in COVID-19 testing demand, healthcare regulation and reimbursement, competition, pricing controls and rebates, foreign currency movements, litigation, tax audits, supply-chain and manufacturing adjustments, and the ability to sustain post-pandemic procedure volumes and diagnostic growth.
Important Facts for Investors to Verify
- Whether COVID-19 testing demand declines faster than expected and the resulting effect on Diagnostics revenue, inventories, capacity utilization, and margins.
- The remaining timing and cash impact of the $500 million to $625 million diagnostic-network restructuring plan.
- The sustainability of underlying, non-COVID-19 sales growth, particularly in Medical Devices, FreeStyle Libre, core diagnostics, and Nutritionals.
- Future operating margins after restructuring charges, litigation costs, higher commercial spending, and amortization.
- Debt maturities, refinancing needs, credit ratings, and the balance between dividends, share repurchases, acquisitions, and debt reduction.
- Developments in disclosed litigation, environmental matters, tax audits, healthcare regulation, and reimbursement policies.